Cyberonics, Sorin Seek Critical Mass With Merger
This article was originally published in The Gray Sheet
Executive Summary
The yet-to-be-named combined company is predicting big opportunities, particularly, heart failure, sleep apnea and cardiac surgery.
You may also be interested in...
Vagus Nerve Stimulation For Heart Failure Fails To Impress, But BioControl Not Bothered
Boston Scientific and Cyberonics report disappointing data on vagus nerve stimulation to treat heart failure at the European Society of Cardiology conference in Barcelona. But another developer of a VNS system for heart failure, BioControl, says the results won’t affect its chances for approval.
Merck Suit Against Medicare: Constitutional Arguments Are Scathing, But Are They Persuasive?
A suit designed to test the limits of the protections against judicial review that are embedded in the IRA could have more traction, some legal scholars suggest.